TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Consensus Price Target of $2.67 According to Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has earned an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $2.67.

Several equities analysts have weighed in on TCRX shares. Lifesci Capital downgraded shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. HC Wainwright lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Tuesday, September 8th. Weiss Ratings cut shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Benchmark restated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday, August 13th. Finally, Wedbush cut TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a report on Wednesday, September 2nd.

TScan Therapeutics Stock Down 17.6%

TCRX opened at $0.23 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37. The company has a market cap of $15.47 million, a price-to-earnings ratio of -0.25 and a beta of 1.15. TScan Therapeutics has a one year low of $0.22 and a one year high of $2.57. The business’s fifty day moving average is $0.53 and its two-hundred day moving average is $0.85.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%.The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.88 million. Analysts anticipate that TScan Therapeutics will post -0.79 EPS for the current fiscal year.

Institutional Trading of TScan Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TCRX. Landscape Capital Management L.L.C. purchased a new stake in TScan Therapeutics during the 2nd quarter worth about $25,000. Public Employees Retirement System of Ohio purchased a new position in TScan Therapeutics in the 1st quarter valued at about $28,000. Bank of America Corp DE purchased a new position in TScan Therapeutics in the 2nd quarter valued at about $48,000. Kestra Advisory Services LLC acquired a new stake in shares of TScan Therapeutics during the 1st quarter worth about $63,000. Finally, NewEdge Wealth LLC purchased a new stake in shares of TScan Therapeutics during the second quarter worth about $90,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell therapies for patients with cancer. The company’s approach is designed to harness the ability of T cells to recognize cancer-associated antigens presented on the surface of tumor cells, including targets that may be difficult to address with other forms of cell therapy.

TScan’s pipeline includes TCR-engineered therapies for both hematologic malignancies and solid tumors.